Viewing Study NCT02554357


Ignite Creation Date: 2025-12-24 @ 6:35 PM
Ignite Modification Date: 2026-02-20 @ 11:49 PM
Study NCT ID: NCT02554357
Status: COMPLETED
Last Update Posted: 2016-09-08
First Post: 2015-07-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Quality of Analgesia After Interscalene Block After Arthroscopic Shoulder Surgery
Sponsor: North American Institute for Continuing Medical Education (NAICE)
Organization:

Study Overview

Official Title: Quality of Analgesia After Interscalene Block With Bupivacaine and Exparel® vs. Bupivacaine Alone After Arthroscopic Shoulder Surgery
Status: COMPLETED
Status Verified Date: 2016-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Shoulder arthroscopic causes post operative pain that outlasts analgesia provided by single injection nerve blocks.
Detailed Description: The interscalene brachial plexus block (ISBPB) is a common analgesic technique for procedures of the shoulder and upper arm.

Moreover, the incidence of rebound pain is well documented and is often of considerable discomfort to patients, who may quickly go from little or no pain to moderate-severe pain. Continuous nerve block techniques with home ambulatory catheters are currently utilized to manage postoperative pain.This study is designed to compare the level and duration of pain control of Exparel® injected after bupivacaine via stop-cock connected syringes and bupivacaine alone for ISBPB.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: